Cargando…
Myeloid PTP1B deficiency protects against atherosclerosis by improving cholesterol homeostasis through an AMPK-dependent mechanism
OBJECTIVE: Atherosclerosis is a chronic inflammatory process induced by the influx and entrapment of excess lipoproteins into the intima media of arteries. Previously, our lab demonstrated that systemic PTP1B inhibition protects against atherosclerosis in preclinical LDLR(−/−) models. Similarly, it...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10568790/ https://www.ncbi.nlm.nih.gov/pubmed/37828508 http://dx.doi.org/10.1186/s12967-023-04598-2 |
_version_ | 1785119425667530752 |
---|---|
author | Oliver, Helk Ruta, Dekeryte Thompson, Dawn Kamli-Salino, Sarah Philip, Sam Wilson, Heather M. Mody, Nimesh Delibegovic, Mirela |
author_facet | Oliver, Helk Ruta, Dekeryte Thompson, Dawn Kamli-Salino, Sarah Philip, Sam Wilson, Heather M. Mody, Nimesh Delibegovic, Mirela |
author_sort | Oliver, Helk |
collection | PubMed |
description | OBJECTIVE: Atherosclerosis is a chronic inflammatory process induced by the influx and entrapment of excess lipoproteins into the intima media of arteries. Previously, our lab demonstrated that systemic PTP1B inhibition protects against atherosclerosis in preclinical LDLR(−/−) models. Similarly, it was shown that myeloid-specific PTP1B ablation decreases plaque formation and ameliorates dyslipidaemia in the ApoE(−/−) model of atherosclerosis. We hypothesized that the relevant improvements in dyslipidaemia following modification of PTP1B activation may either result from changes in hepatic cholesterol biosynthesis and/or increased uptake and degradation by liver-resident macrophages. We examined this in animal models and patients with coronary artery disease. METHODS: In this study, we determined the cholesterol-lowering effect of myeloid-PTP1B deletion in mice fed a high-fat high-cholesterol diet and examined effects on total cholesterol levels and lipoprotein profiles. We also determined the effects of PTP1B inhibition to oxLDL-C challenge on foam cell formation and cholesterol efflux in human monocytes/macrophages. RESULTS: We present evidence that myeloid-PTP1B deficiency significantly increases the affinity of Kupffer cells for ApoB containing lipoproteins, in an IL10-dependent manner. We also demonstrate that PTP1B inhibitor, MSI-1436, treatment decreased foam cell formation in Thp1-derived macrophages and increased macrophage cholesterol efflux to HDL in an AMPK-dependent manner. We present evidence of three novel and distinct mechanisms regulated by PTP1B: an increase in cholesterol efflux from foam cells, decreased uptake of lipoproteins into intra-lesion macrophages in vitro and a decrease of circulating LDL-C and VLDL-C in vivo. CONCLUSIONS: Overall, these results suggest that myeloid-PTP1B inhibition has atheroprotective effects through improved cholesterol handling in atherosclerotic lesions, as well as increased reverse cholesterol transport. Trial registration Research registry, researchregistry 3235. Registered 07 November 2017, https://www.researchregistry.com/browse-the-registry#home/registrationdetails/5a01d0fce7e1904e93e0aac5/. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12967-023-04598-2. |
format | Online Article Text |
id | pubmed-10568790 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-105687902023-10-13 Myeloid PTP1B deficiency protects against atherosclerosis by improving cholesterol homeostasis through an AMPK-dependent mechanism Oliver, Helk Ruta, Dekeryte Thompson, Dawn Kamli-Salino, Sarah Philip, Sam Wilson, Heather M. Mody, Nimesh Delibegovic, Mirela J Transl Med Research OBJECTIVE: Atherosclerosis is a chronic inflammatory process induced by the influx and entrapment of excess lipoproteins into the intima media of arteries. Previously, our lab demonstrated that systemic PTP1B inhibition protects against atherosclerosis in preclinical LDLR(−/−) models. Similarly, it was shown that myeloid-specific PTP1B ablation decreases plaque formation and ameliorates dyslipidaemia in the ApoE(−/−) model of atherosclerosis. We hypothesized that the relevant improvements in dyslipidaemia following modification of PTP1B activation may either result from changes in hepatic cholesterol biosynthesis and/or increased uptake and degradation by liver-resident macrophages. We examined this in animal models and patients with coronary artery disease. METHODS: In this study, we determined the cholesterol-lowering effect of myeloid-PTP1B deletion in mice fed a high-fat high-cholesterol diet and examined effects on total cholesterol levels and lipoprotein profiles. We also determined the effects of PTP1B inhibition to oxLDL-C challenge on foam cell formation and cholesterol efflux in human monocytes/macrophages. RESULTS: We present evidence that myeloid-PTP1B deficiency significantly increases the affinity of Kupffer cells for ApoB containing lipoproteins, in an IL10-dependent manner. We also demonstrate that PTP1B inhibitor, MSI-1436, treatment decreased foam cell formation in Thp1-derived macrophages and increased macrophage cholesterol efflux to HDL in an AMPK-dependent manner. We present evidence of three novel and distinct mechanisms regulated by PTP1B: an increase in cholesterol efflux from foam cells, decreased uptake of lipoproteins into intra-lesion macrophages in vitro and a decrease of circulating LDL-C and VLDL-C in vivo. CONCLUSIONS: Overall, these results suggest that myeloid-PTP1B inhibition has atheroprotective effects through improved cholesterol handling in atherosclerotic lesions, as well as increased reverse cholesterol transport. Trial registration Research registry, researchregistry 3235. Registered 07 November 2017, https://www.researchregistry.com/browse-the-registry#home/registrationdetails/5a01d0fce7e1904e93e0aac5/. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12967-023-04598-2. BioMed Central 2023-10-12 /pmc/articles/PMC10568790/ /pubmed/37828508 http://dx.doi.org/10.1186/s12967-023-04598-2 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Oliver, Helk Ruta, Dekeryte Thompson, Dawn Kamli-Salino, Sarah Philip, Sam Wilson, Heather M. Mody, Nimesh Delibegovic, Mirela Myeloid PTP1B deficiency protects against atherosclerosis by improving cholesterol homeostasis through an AMPK-dependent mechanism |
title | Myeloid PTP1B deficiency protects against atherosclerosis by improving cholesterol homeostasis through an AMPK-dependent mechanism |
title_full | Myeloid PTP1B deficiency protects against atherosclerosis by improving cholesterol homeostasis through an AMPK-dependent mechanism |
title_fullStr | Myeloid PTP1B deficiency protects against atherosclerosis by improving cholesterol homeostasis through an AMPK-dependent mechanism |
title_full_unstemmed | Myeloid PTP1B deficiency protects against atherosclerosis by improving cholesterol homeostasis through an AMPK-dependent mechanism |
title_short | Myeloid PTP1B deficiency protects against atherosclerosis by improving cholesterol homeostasis through an AMPK-dependent mechanism |
title_sort | myeloid ptp1b deficiency protects against atherosclerosis by improving cholesterol homeostasis through an ampk-dependent mechanism |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10568790/ https://www.ncbi.nlm.nih.gov/pubmed/37828508 http://dx.doi.org/10.1186/s12967-023-04598-2 |
work_keys_str_mv | AT oliverhelk myeloidptp1bdeficiencyprotectsagainstatherosclerosisbyimprovingcholesterolhomeostasisthroughanampkdependentmechanism AT rutadekeryte myeloidptp1bdeficiencyprotectsagainstatherosclerosisbyimprovingcholesterolhomeostasisthroughanampkdependentmechanism AT thompsondawn myeloidptp1bdeficiencyprotectsagainstatherosclerosisbyimprovingcholesterolhomeostasisthroughanampkdependentmechanism AT kamlisalinosarah myeloidptp1bdeficiencyprotectsagainstatherosclerosisbyimprovingcholesterolhomeostasisthroughanampkdependentmechanism AT philipsam myeloidptp1bdeficiencyprotectsagainstatherosclerosisbyimprovingcholesterolhomeostasisthroughanampkdependentmechanism AT wilsonheatherm myeloidptp1bdeficiencyprotectsagainstatherosclerosisbyimprovingcholesterolhomeostasisthroughanampkdependentmechanism AT modynimesh myeloidptp1bdeficiencyprotectsagainstatherosclerosisbyimprovingcholesterolhomeostasisthroughanampkdependentmechanism AT delibegovicmirela myeloidptp1bdeficiencyprotectsagainstatherosclerosisbyimprovingcholesterolhomeostasisthroughanampkdependentmechanism |